Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc. develops innovative cancer immunotherapies, focusing on CAR-T cell therapy to improve treatment outcomes for cancer patients by leveraging the immune system's capabilities. Founded in 2015 and headquartered in Tokyo, Japan, Noile-Immune Biotech Inc. specializes in the development of advanced cancer immunotherapies.

The company raised JPY 2. 38 billion in Series C funding on March 22, 2021, led by investors including Binex Holdings, Dai-ichi Life Insurance, and Shibuya Corporation. Noile-Immune has completed five deals to date. Noile-Immune Biotech Inc.

specializes in developing innovative cancer immunotherapies, particularly CAR-T cell therapy, which utilizes the immune system to effectively target and eliminate cancer cells. Their leading product is based on NOILE technology, enhancing CAR-T therapies' versatility and scalability. Collaborating with healthcare providers and research institutions, they aim to serve hospitals, oncology clinics, and biopharmaceutical partners across North America, Europe, and parts of Asia, catering specifically to cancer patients' treatment needs. In the most recent fiscal year, 2020, Noile-Immune Biotech Inc.

reported revenue of JPY 983,493. Noile-Immune Biotech plans to use the JPY 2. 38 billion raised in Series C funding to conduct clinical trials for its lead pipeline, NIB-101, which focuses on gene-modified immune cell therapies, primarily CAR-T cells utilizing their core PRIME technology. The company is targeting expansion into new markets, with plans to enhance its presence in North America and Europe by the end of 2023, while also advancing its product offerings in the oncology sector.